The historical rank and industry rank for Champions Oncology's FCF Margin % or its related term are showing as below:
CSBR'
s FCF Margin % Range Over the Past 10 Years
Min: -60.19 Med: -5.03 Max: 12.29
Current: 7.02
During the past 13 years, the highest FCF Margin % of Champions Oncology was 12.29%. The lowest was -60.19%. And the median was -5.03%.
CSBR's FCF Margin % is ranked better than 80.21% of 960
companies
in the Biotechnology industry
Industry Median: -85.21
vs CSBR: 7.02
Champions Oncology FCF Margin % Related Terms
Champions Oncology FCF Margin % Historical Data
* Premium members only.
The historical data trend for Champions Oncology's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Champions Oncology's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Champions Oncology FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Champions Oncology's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Champions Oncology's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Champions Oncology (CSBR) has a FCF Margin % of -8.31% as of Jan. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Champions Oncology and its competitors. According to the industry distribution chart, Champions Oncology ranks #190 out of 960 companies in the Biotechnology industry, placing it in the top 19.8%.
Is Champions Oncology's FCF Margin % too high?
Champions Oncology's current FCF Margin % is -8.31%. Based on the distribution chart, Champions Oncology ranks #190 out of 960 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Champions Oncology has a GF Score™ of 64/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Champions Oncology's FCF Margin % compare to ANVS and HYFT?
According to the Biotechnology industry distribution chart, Champions Oncology ranks #190 out of 960 companies for FCF Margin %. This places Champions Oncology in the top 20% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Champions Oncology and its competitors. Champions Oncology's current FCF Margin % is -8.31%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Champions Oncology stock overvalued right now?
Based on GuruFocus' analysis, Champions Oncology (CSBR) is currently considered Fairly Valued. The stock's GF Value™ is $6.62, compared to a current price of $6.08 — trading 8.2% below its estimated fair value. The current FCF Margin % is -8.31%. Champions Oncology's overall GF Score™ is 64/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Champions Oncology (CSBR), the current FCF Margin % is -8.31% as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Champions Oncology (CSBR) Overvalued in 2026?
Based on GuruFocus' analysis, Champions Oncology stock appears to be undervalued.
The current stock price of $6.08 is trading 8.2% below its estimated GF Value™ of $6.62.
GuruFocus considers Champions Oncology to be Fairly Valued.
Key valuation signals for CSBR:
FCF Margin %: -8.31%
GF Value™: $6.62 vs. price of $6.08 (8.2% below fair value)
No single metric tells the full story. See the CSBR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.
64GF Score
Get the complete analysis for CSBR
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSBR has been successfully added to your 
